FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 50 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer MOST POPULAR Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 The Benefits of Yoga During Cancer and How to Get Started August 2, 2022 Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer January 12, 2022 For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target January 3, 2019 Load more HOT NEWS How Do Black People with Cancer View Clinical Research? EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab 10 Tips for National Cancer Prevention Month Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe
